CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
IPO Year: 2014
Exchange: NASDAQ
Website: caredx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/15/2025 | $28.00 → $24.00 | Underweight → Equal Weight | Wells Fargo |
| 8/28/2024 | $28.00 | Underweight | Wells Fargo |
| 8/19/2024 | $40.00 | Neutral → Buy | BTIG Research |
| 5/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2024 | $15.00 | Hold → Buy | Craig Hallum |
| 11/9/2023 | $10.00 | Equal-Weight → Overweight | Stephens |
| 8/15/2023 | $12.00 | Mkt Perform → Outperform | Raymond James |
| 5/11/2023 | Buy → Neutral | BTIG Research | |
| 3/7/2023 | $19.00 → $9.00 | Overweight → Equal-Weight | Stephens |
| 3/3/2023 | $26.00 → $9.00 | Buy → Hold | Craig Hallum |
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously
Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00
BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00
Raymond James downgraded CareDx from Outperform to Mkt Perform
Craig Hallum upgraded CareDx from Hold to Buy and set a new price target of $15.00
Stephens upgraded CareDx from Equal-Weight to Overweight and set a new price target of $10.00
Raymond James upgraded CareDx from Mkt Perform to Outperform and set a new price target of $12.00
BTIG Research downgraded CareDx from Buy to Neutral
Stephens downgraded CareDx from Overweight to Equal-Weight and set a new price target of $9.00 from $19.00 previously
Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $9.00 from $26.00 previously
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G - CareDx, Inc. (0001217234) (Subject)
144 - CareDx, Inc. (0001217234) (Subject)
10-Q - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
DEFA14A - CareDx, Inc. (0001217234) (Filer)
DEF 14A - CareDx, Inc. (0001217234) (Filer)
SCHEDULE 13G/A - CareDx, Inc. (0001217234) (Subject)
8-K - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
SCHEDULE 13G/A - CareDx, Inc. (0001217234) (Subject)
8-K - CareDx, Inc. (0001217234) (Filer)
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to
Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. Please reference Conference ID: CareDx. To listen to
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-877-300-8521 for domestic callers or 1-412-317-6026 for international callers. Please reference Conference ID: 10181676. To listen to a live webcast,
MediGO Platform Aims to Improve Access to Donated Organs and Shorten Transplant Wait Times Acquisition Expands CareDx Digital Health Portfolio and Establishes Footprint in OPO Market CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the acquisition of MediGO, Inc. in a strategic move to expand its digital health portfolio to serve the organ procurement organization (OPO) market while also bolstering its pre-transplant offerings aimed at shortening transplant wait times and increasing access to d
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. Please reference Conference ID: 22026935. To listen to a live webcast, pl
CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. "We're pleased to welcome Bryan to our Board," said Michael Goldberg, CareDx Board Chairperson. "His financial expertise, operating background and deep understanding of revenue cycle management in molecular diagnostics will allow him to make meaningful contributions to our Board." Riggsbee previously served as Chief Financial Officer at Myr
Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson. CareDx will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, Chief Financial Officer Abh
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc. "Grace is a seasoned leader who has founded and managed multiple biotechnology and healthcare businesses," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "As we continue t
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately. "We are in a pivotal time for Team Summit as we seek to expand our portfolio of pipeline assets through potential collaborations and possible acquisitions," said Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Ankur's leadership and experience will be critical in ensuring the financial viability and excellence of our organization. Ankur's wealth of knowledge across all aspects of finance will add substantial value to our organization as we take the next step in seeking to make
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. Concurrent with the appointment of Dr. Seeto as President and Chief Executive Officer of CareDx in November 2020, Dr. Maag had agreed to serve as Executive Chairman of the company's Board of Directors to facilitate an orderly transition. Now that this transition is
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of patient advocate, political leader, and former state senator Art Torres to its Board of Directors. Torres began his career working alongside Cesar Chavez to fight against pesticide exposure that was killing and sickening farm workers in California. He later served for 20 years in the California legislature, chairing the State Assembly's Health Committee, and then was
TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay on in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr. Konrad over the next approximately three months. "I want to take this opportunity on behalf of all of us at Medexus to thank Roland for all of his efforts and dedicated service and to wish him the very best in his fut
First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please
AlloSure Heart is Now Validated and Commercially Available for Pediatric Heart Transplant Patients Under 15 AlloSure Kidney is Now Validated and Commercially Available for Simultaneous Pancreas-Kidney Transplant Patients CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. Both indications are appro
Full Year 2024 Revenue Grew 19% to $334 Million Expects Full Year 2025 Revenue of $365 Million to $375 Million CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenue of $86.6 million, increased 32% year-over-year Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, increased 14% year-over-year GAAP net income of $87.7 million, non-GAAP net income of $10.7 million, and positive adjusted EBITDA of $9.8 million, a significant improvement from the fourth quarter 2023 Cash flow from operations of
All Patent Claims Asserted Against CareDx are Found to Be Invalid CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor. The District Court ruled that the patents asserted against CareDx are invalid. The Court reached this determination because the patents failed to describe the claimed invention in sufficient detail. CareDx believes that the Court's decision brings this lawsuit to its rightful legal outcome and is
New Data from the ACROBAT Study Shows AlloHeme Detects Cancer Relapse with Clinically Meaningful Lead Time CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 12-15, 2025 in Honolulu, Hawaii. In an oral presentation, a one-year interim analysis of the ACROBAT prospective, multi-center study showed that AlloHeme™ is an accurate and sens
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to
Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-year. Testing Services volume of approximately 45,500 increased 14% year-over-year. Revenu
CareDx, Inc. (NASDAQ:CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDx's management is scheduled to present on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time (7:30 p.m Eastern Time). To listen to the webcast, please visit the Events & Presentations section of CareDx's Investor Relations website at: investors.caredx.com. About CareDx – The Transplant Company CareD